Articles tagged "Immunosuppression"

2018 American Transplant Congress
Analyzing Transplant Medication Myths
R. Krislock, J. Brandenberger, P. Stracener, A. Weiss, K. Wipperling, C. Kuhr.
Division of Transplant, Virginia Mason Medical Center, Seattle, WA.
Patients may misconstrue the amount of medications required for transplantation, expecting to take “handfuls” of medications for life. This study aims to determine the change…
2018 American Transplant Congress
Delayed Achievement of Therapeutic Tacrolimus Levels after Renal Transplantation is Not Associated with Increased Incidence of Early Acute Rejection: Single-Center Results
R. Marshall, J. Brandenberger, A. Cantafio, J. Halldorson, R. Bakthavatsalam, A. Dick, S. Rayhill, J. Reyes, J. Perkins.
Division of Transplant Surgery, Department of Surgery, University of Washington, Seattle, WA.
Induction therapy followed by maintenance with a calcineurin inhibitor aims to minimize the incidence of early rejection and optimize the potential for allograft function. However…
2018 American Transplant Congress
Belatacept Maintenance Immunosuppression Use and Outcomes in the Real-World Clinical Setting Using OPTN/UNOS Kidney Transplant Registry
S. Sanoff,¹ K. Ravindra,¹ W. Irish.^1,2
¹Duke University Medical Center, Durham, NC; ²CTI Consulting, Raleigh, NC.
Introduction:Belatacept (BEL) was FDA approved for Kidney Transplantation (KTx) June 2011. It has largely been evaluated in two controlled trials (N Engl J Med 2016;374:333-43).…
2018 American Transplant Congress
Validation of an Integrative and Dynamic Prognostic Score for Response to Therapy in Solid Organ Transplants
A. Loupy, O. Aubert, D. Viglietti, C. Legendre, D. Glotz, C. Lefaucheur.
Paris Translational Center for Organ Transplantation, Paris, France.
Drug development in transplantation has diminished due to the lack of suitable endpoints for predicting graft failure. We sought to validate the performance of an…
2018 American Transplant Congress
Cost Impacts of Alternative Kidney Transplant Immunosuppression: A National Cohort Study
K. Lentine,¹ D. Axelrod,² V. Dharnidharka,³ H. Xiao,¹ D. Brennan,⁴ D. Segev,⁴ H. Randall,¹ R. Ouseph,¹ A. Naik,⁵ N. Lam,⁶ T. Alhamad,³ B. Kasiske,⁷ G. Hess,⁸ M. Schnitzler.¹
¹Saint Louis Univ, St. Louis; ²Lahey Clinic, Burlington; ³Washington Univ, St. Louis; ⁴Johns Hopkins, Baltimore; ⁵Univ Michigan, Ann Arbor; ⁶Univ Alberta, Edmonton, Canada; ⁷Hennepin County, Minneapolis; ⁸Symphony Health, Conshohocken.
Economic outcomes are increasingly considered along with clinical efficacy to guide choice of alternative therapies. We examined the cost impact of kidney transplant (KTx) induction…
2018 American Transplant Congress
Clinical Validation of a Novel ELISpot-Based In Vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients
B. Banas,¹ D. Steubl,² L. Renders,² D. Chittka,¹ M. Banas,¹ T. Wekerle,³ M. Koch,⁴ O. Witzke,⁵ A. Muehlfeld,⁶ C. Sommerer,⁷ A. Habicht,⁸ C. Hugo,⁹ T. Huenig,¹⁰ M. Lindemann,⁵ T. Schmidt,¹¹ A. Rascle,¹¹ S. Barabas,¹¹ L. Deml,¹¹ R. Wagner,^1,11 B. Kraemer,¹² B. Krueger.¹²
¹University Clinic, Regensburg, Germany; ²Clinic rechts der Isar TUM, Munich, Germany; ³Medical University, Vienna, Austria; ⁴University Clinic, Hamburg-Eppendorf, Germany; ⁵University Hospital, Essen, Germany; ⁶Uniklinik RWTH, Aachen, Germany; ⁷University Hospital, Heidelberg, Germany; ⁸LMU Medical Center, Munich, Germany; ⁹University Hospital, Dresden, Germany; ¹⁰University Hospital, Wuerzburg, Germany; ¹¹Lophius Biosciences, Regensburg, Germany; ¹²UMM Uni. Heidelberg, Mannheim, Germany.
Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause ofCMV reactivation and associated complications in solid-organ transplantation. Reliably assessing CMV-CMI is desirable to individually…
2018 American Transplant Congress
Biomaterial-Based Localized and Controlled Delivery of Tofacitinib to Actuate Enhanced Costimulation Blockade and Promote Long-Term Transplant Survival
G. Raimondi,¹ P. Majumder,² V. Ivanova,¹ X. Calderon-Colon,³ A. Mirdad,¹ M. Iglesias Lozano,¹ W. Lee,¹ G. Brandacher,¹ J. Schneider,² J. Patrone.³
¹Johns Hopkins School of Medicine, Baltimore; ²National Cancer Institute, Frederick; ³Johns Hopkins Applied Physics Laboratory, Laurel.
Complications from long-term use of calcineurin inhibitors remain a major issue for transplant patients and alternative therapies are highly needed. We investigated two innovative drug…
2018 American Transplant Congress
Optimal Anti-Thymocyte Globulin Dose for Induction Immunosuppression in Kidney Transplantation
A. Mitrokhin, J. Goldman, B. Trivedi, V. Vidyasagar, N. Vadivel, M. Hart.
Organ Transplant Program, Swedish Medical Center, Seattle, WA.
Anti-thymocyte globulin (ATG) is used as induction immunosuppression in kidney transplantation to prevent allograft rejection. ATG causes dose-dependent lymphocyte depletion, yet optimal dose is unknown.…
2018 American Transplant Congress
Decreased Expression of Pro-Carcinogenic Genes Following Tacrolimus to Sirolimus Conversion in Liver Transplant Recipients
M. Bhat,¹ E. Pasini,¹ C. Baciu,¹ S. Kurian,² J. Levitsky.³
¹Multi Organ Transplant Program, University Health Network, Toronto, Canada; ²Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; ³Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University, Chicago.
Long-term survival post-transplant is significantly impacted by malignancy. mTOR-inhibitors (mTORis) have anti-neoplastic properties and are associated with a decreased incidence of certain malignancies compared to…
2018 American Transplant Congress
Assessment of Peak Levels and Metabolism Rates in African American (AA) and Non-AA Kidney Transplant Recipients (KTR) on Immediate-Release Tacrolimus (IR-tac)
T. Horwedel,¹ R. Sodhi,² D. Tsapapas,³ M. Mills,⁴ S. Patel,⁴ G. Towns.⁵
¹Barnes-Jewish Hospital, St. Louis, MO; ²St. Louis University, St. Louis, MO; ³Columbia University, New York, NY; ⁴Veloxis Pharmaceuticals, Cary, NC; ⁵University of Alabama, Birmingham, AL.
Trough-to-daily dose (C/D) ratio has been used as a simple method for evaluation of IR-tac metabolism rate. Recent studies have shown that fast metabolizers defined…